A health economic model to assess the cost-effectiveness of PEG IFN α-2a and ribavirin in patients with mild chronic hepatitis C

Journal of Viral Hepatitis

Volumn 14, Issue 8, 2007, Pages 523-536

  Gerkens, S ^a   Nechelput, M ^b   Annemans, L ^c   Peraux, B ^b   Mouchart, M ^d   Beguin, C ^a   Horsmans, Y ^a  

^a CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^b NV Roche SA   (Belgium)

^c GHENT UNIVERSITY   (Belgium)

^d UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

Author keywords

Cost effectiveness; Economic; Markov model; Mild chronic hepatitis C; Pegylated interferon

Indexed keywords

ALPHA2B INTERFERON; PEGINTERFERON ALPHA2A; RIBAVIRIN;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; DISEASE SEVERITY; DRUG COST; DRUG EFFICACY; GENOTYPE; HEALTH ECONOMICS; HEALTH INSURANCE; HEPATITIS C; HUMAN; MAJOR CLINICAL STUDY; MONTE CARLO METHOD; OUTCOME ASSESSMENT; PATIENT MONITORING; PRIORITY JOURNAL; PROBABILITY; QUALITY ADJUSTED LIFE YEAR; RANDOMIZED CONTROLLED TRIAL; SENSITIVITY ANALYSIS;

ANTIVIRAL AGENTS; BELGIUM; COMPUTER SIMULATION; COST-BENEFIT ANALYSIS; DRUG COSTS; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2A; MARKOV CHAINS; MIDDLE AGED; MODELS, ECONOMETRIC; POLYETHYLENE GLYCOLS; QUALITY-ADJUSTED LIFE YEARS; RIBAVIRIN;

EID: 34447567165     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/j.1365-2893.2006.00831.x     Document Type: Article

References (34)

1. Shepherd J, Waugh N, Hewitson P. Combination therapy (interferon alfa and ribavirin) in the treatment of chronic hepatitis C: a rapid and systematic review. Health Technol Assess 2000 4 (33 1 67.
2. Van Damme P, Thyssen A, Van Loock F. Epidemiology of hepatitis C in Belgium: present and future. Acta Gastroenterol Belg 2002 65 (2 78 79.
3. Renard F, Autier M, Doumont D. L'hépatite C en Belgique, comment améliorer le dépistage et la prévention Belgique : Ecole de santé Publique, Unité d'Education pour la santé, Série de dossiers techniques CFB, Report No. 05-34, 27 pp.
4. Delwaide J. Economic evaluation of chronic hepatitis C treatment by interferon-ribavirin combination therapy in Belgium. Acta Gastroenterol Belg 2002 65 (4 233 236.
5. Sullivan SD, Jensen DM, Bernstein DE et al. Cost-effectiveness of combination peginterferon alpha-2a and ribavirin compared with interferon alpha-2b and ribavirin in patients with chronic hepatitis C. Am J Gastroenterol 2004 99 (8 1490 1496.
6. Annemans L, Warie H, Nechelput M, Peraux B. A health economic model to assess the long term effects and cost-effectiveness of PEG IFN alpha-2a in hepatitis C virus infected patients. Acta Gastroenterol Belg 2004 67 (1 1 8.
7. Alberti A. What is 'mild' chronic hepatitis C? Hepatol Rev 2005 2 : 19 23.
8. Salomon JA, Weinstein MC, Hammitt JK, Goldie SJ. Empirically calibrated model of hepatitis C virus infection in the United States. Am J Epidemiol 2002 156 (8 761 773.
9. Michielsen P, Brenard R, Bourgeois N et al. Hepatitis C: screening, treatment and prevention practical guidelines. Acta Gastroenterol Belg 2003 66 (1 15 19.
10. Wong JB, Koff RS. Watchful waiting with periodic liver biopsy versus immediate empirical therapy for histologically mild chronic hepatitis C. A cost-effectiveness analysis. Ann Intern Med 2000 133 (9 665 675.
11. Levine RA. Treating histologically mild chronic hepatitis C: monotherapy, combination therapy, or tincture of time? Ann Intern Med 1998 129 (4 323 326.
12. Drummond MF, O'Brien BJ, Stoddart GL, Torrance GW. Methods for the Economic Evaluation of Health Care Programmes, 2nd edn. Oxford : Oxford University Press, 1997.
13. Sonnenberg FA, Beck JR. Markov models in medical decision making: a practical guide. Med Decis Making 1993 13 (4 322 338.
14. Briggs A, Sculpher M. An introduction to Markov modelling for economic evaluation. Pharmacoeconomics 1998 13 (4 397 409.
15. Fried MW, Shiffman ML, Reddy KR et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002 347 (13 975 982.
16. Hadziyannis SJ, Sette H Jr., Morgan TR et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004 140 (5 346 355.
17. Salomon JA, Weinstein MC, Hammitt JK, Goldie SJ. Cost-effectiveness of treatment for chronic hepatitis C infection in an evolving patient population. JAMA 2003 290 (2 228 237.
18. Younossi ZM, Singer ME, McHutchison JG, Shermock KM. Cost effectiveness of interferon alpha2b combined with ribavirin for the treatment of chronic hepatitis C. Hepatology 1999 30 (5 1318 1324.
19. Bennett WG, Inoue Y, Beck JR, Wong JB, Pauker SG, Davis GL. Estimates of the cost-effectiveness of a single course of interferon-alpha 2b in patients with histologically mild chronic hepatitis C. Ann Intern Med 1997 127 (10 855 865.
20. Sagmeister M, Wong JB, Mullhaupt B, Renner EL. A pragmatic and cost-effective strategy of a combination therapy of interferon alpha-2b and ribavirin for the treatment of chronic hepatitis C. Eur J Gastroenterol Hepatol 2001 13 (5 483 488.
21. Sennfalt K, Reichard O, Hultkrantz R, Wong JB, Jonsson D. Cost-effectiveness of interferon alfa-2b with and without ribavirin as therapy for chronic hepatitis C in Sweden. Scand J Gastroenterol 2001 36 (8 870 876.
22. Siebert U, Sroczynski G, Rossol S et al. Cost effectiveness of peginterferon alpha-2b plus ribavirin versus interferon alpha-2b plus ribavirin for initial treatment of chronic hepatitis C. Gut 2003 52 (3 425 432.
23. Kim WR, Poterucha JJ, Hermans JE et al. Cost-effectiveness of 6 and 12 months of interferon-alpha therapy for chronic hepatitis C. Ann Intern Med 1997 127 (10 866 874.
24. Wong JB, Poynard T, Ling MH, Albrecht JK, Pauker SG. Cost-effectiveness of 24 or 48 weeks of interferon alpha-2b alone or with ribavirin as initial treatment of chronic hepatitis C. International Hepatitis Interventional Therapy Group. Am J Gastroenterol 2000 95 (6 1524 1530.
25. Jusot JF, Colin C. Cost-effectiveness analysis of strategies for hepatitis C screening in French blood recipients. Eur J Public Health 2001 11 (4 373 379.
26. Wong JB, Nevens F. Cost-effectiveness of peginterferon alfa-2b plus ribavirin compared to interferon alfa-2b plus ribavirin as initial treatment of chronic hepatitis C in Belgium. Acta Gastroenterol Belg 2002 65 (2 110 111.
27. Cleemput I, Crott R, Vrijens F, Huybrechts M, Van Wilder P, Ramaekers D. Recommandations provisoires pour les évaluations pharmacoé conomiques en Belgique. Bruxelles : Centre fédéral d'expertise des soins de santé (KCE), 2006 6 A.D. May. Report No.: KCE Reports vol. 28B. Ref. D/2006/10.273/11.7.
28. Grieve R, Roberts J, Wright M et al. Cost effectiveness of interferon alpha or peginterferon alpha with ribavirin for histologically mild chronic hepatitis C. Gut 2006 55 (9 1332 1338.
29. Shepard DS. Cost-effectiveness. In : Gold MR, Siegel JE, Russell LB, Weinstein MC, eds. Health and Medicine. New York : Oxford University Press, 1996. J Ment Health Policy Econ 1999 2 (2 91 92.
30. Blackmore CC, Ramsey SD, Mann FA, Deyo RA. Cervical spine screening with CT in trauma patients: a cost-effectiveness analysis. Radiology 1999 212 (1 117 125.
31. Roze S, Valentine WJ, Evers T, Palmer AJ. Acarbose in addition to existing treatments in patients with type 2 diabetes: health economic analysis in a German setting. Curr Med Res Opin 2006 22 (7 1415 1424.
32. de Torres M, Poynard T. Risk factors for liver fibrosis progression in patients with chronic hepatitis C. Ann Hepatol 2003 2 (1 5 11.
33. McCabe C, Dixon S. Testing the validity of cost-effectiveness models. Pharmacoeconomics 2000 17 (5 501 513.
34. Hammerschmidt T, Goertz A, Wagenpfeil S, Neiss A, Wutzler P, Banz K. Validation of health economic models: the example of EVITA. Value Health 2003 6 (5 551 559.